ATC Group: V03AF04 Calcium levofolinate

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of V03AF04 in the ATC hierarchy

Level Code Title
1 V Various
2 V03 All other therapeutic products
3 V03A All other therapeutic products
4 V03AF Detoxifying agents for antineoplastic treatment
5 V03AF04 Calcium levofolinate

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 30 mg
PAREN - Parenteral 30 mg

Active ingredients in V03AF04

Active Ingredient Description
Levoleucovorin

Levoleucovorin is the pharmacologically active isomer of 5-formyltetrahydrofolic acid. Administration of levoleucovorin can “rescue” normal cells and thereby prevent toxicity of folic acid antagonists such as methotrexate which act by inhibiting dihydrofolate reductase.

Related product monographs

Title Information Source Document Type  
ISOVORIN Solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

France (FR)

Japan (JP)

Spain (ES)

Tunisia (TN)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.